<DOC>
	<DOCNO>NCT00003669</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth endometrial cancer cell . Hormone therapy use arzoxifene hydrochloride may fight endometrial cancer block use estrogen tumor cell PURPOSE : This phase II trial study well arzoxifene hydrochloride work treat woman recurrent , advance , metastatic endometrial cancer .</brief_summary>
	<brief_title>Hormone Therapy With Arzoxifene Hydrochloride Treating Women With Recurrent , Advanced , Metastatic Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective tumor response rate ( complete response partial response ) arzoxifene hydrochloride patient recurrent advance endometrial cancer . II . Determine time progressive disease , time treatment failure , response duration , survival patient recurrent advance endometrial cancer receive arzoxifene hydrochloride . III . Assess safety treatment patient . IV . Measure change serum estradiol , follicle stimulate hormone , luteinizing hormone , sex hormone bind globulin treatment patient . OUTLINE : Patients receive oral arzoxifene hydrochloride daily fix dose . Treatment continue absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : Not specify National Cancer Institute ( NCI ) register trial Eli Lilly sponsor . NCI update record trial complete . In June 2012 , NCI transfer trial Lilly 's clinicaltrials.gov account Lilly update record trial completion date . This trial applicable trial Food Drug Administration Amendments Act 2007 ( FDAAA ) .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent , advance , metastatic endometrial cancer amenable curative surgery radiotherapy Patients previously undergone radical surgery ( minimum total abdominal hysterectomy bisalpingoophorectomy ) , radical radiotherapy , candidate procedure Bidimensionally measurable disease xray , CT scan , MRI , physical exam No papillary serous clear cell carcinoma endometrium Hormone receptor status : Estrogen receptor positive and/or progesterone receptor positive Unknown receptor status patient allow provide ( 1 ) original tumor well moderatelywell differentiate ( 2 ) endometrioid histology PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Menopausal status : Not specify Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( transfusionindependent ) Prothrombin time activate partial thromboplastin time great 1.25 time upper limit normal ( ULN ) Hepatic : Bilirubin great 1.5 time normal ALT AST great 2.5 time ULN ( ALT AST great 5 time ULN presence liver metastasis ) Renal : Creatinine great 1.5 ULN Other : No primary malignancy within past 5 year except adequately treat nonmelanomatous cancer skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy recurrent metastatic endometrial cancer At least 1 year since prior adjuvant chemotherapy Endocrine therapy : No prior antiestrogen therapy stage endometrial cancer At least 12 month time diagnosis since prior raloxifene Prior progesterone treatment allow Radiotherapy : See Disease Characteristics At least 2 week since prior radiotherapy recover Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
</DOC>